The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development. Continuous processing keeps the industry grounded in reaching propelled ESG goals whilst keeping capital spend to a minimum. With the previous release of the ICH Q13 broadening the scope of support for continuous manufacturing as a greener alternative, continuous processing is unstoppable in its efforts to drive formulation efficiency and supply chain resilience across all modalities.

In collaboration with AstraZeneca, Pfizer, Sanofi, and Ultragenyx, the 9th Commercializing Continuous Processing Summit returns to you with a new strategic focus and novel case-studies spanning small molecule, biologics and emerging modalities to secure internal support for your continuous shift, and edge towards first-class, quality therapeutics for patients.

Event link here.